Analysis of blood gas can be a daunting task. However, it is still one of the most useful laboratory tests in managing respiratory and metabolic disorders. Busy medical students have struggled ineffectively with Hasselbach's modification of the Henderson equation, been torn between the Copenhagen and the Boston schools of thought; and lately, been confronted with the radically different strong-ion approach. In modern medical practice, the health provider's time is precious: it is crucial to retain focus on those aspects of clinical medicine that are of key importance. Adoption of an algorithm-based approach in the study of topics that are hard to understand (particularly those that are rooted in clinical physiology) can be extremely advantageous. Handbook of Blood Gas/Acid-Base Interpretation, 2nd edition, is organized in a logical sequence of flow charts that introduce concepts and gradually build upon them. This approach facilitates understanding and retention of the subject matter. Medical students, residents, nurses, and practitioners of respiratory and intensive care will find it possible to quickly grasp the principles underlying respiratory and acid-base physiology, and apply them effectively in clinical decision making.

In Chronic Leukemias and Lymphomas: Clinical Management, a panel of recognized experts in hematological oncology describe the unique biological features of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease. In their integrated surveys of these chronic myeloproliferative and lymphoproliferative disorders, the authors emphasize such unique entities as prolymphocytic leukemias and cutaneous lymphomas. Special emphasis is given to the mechanisms of disease progression with authoritative insights into the promising new era of antineoplastic pharmacology.

The task the editors have set themselves is to survey the field of clinical hemorheology from basic principles to up-to-date research. It is only in a new science like this that it is possible to span the whole field in a book of this size. Hemorheology, as a new approach to the study and management of a wide range of circulatory diseases, is now beginning to appear with increasing frequency in general as well as specialized medical journals. Hemorheology is also just beginning to creep into the undergraduate medical curriculum. Therefore, the majority of graduate doctors are unequipped to assess the place of hemorheology in the overall framework of circulatory physiology and pathology or to assess its relevance to their everyday practice. It is hoped that this book will fill this gap. The approach of the book is interdisciplinary. The first part deals with basic principles of blood flow, circulation and hemorheology. It has been written with the general doctor in mind, who has no special knowledge of hemodynamics and rheological concepts, terminology or methodology. To maintain the emphasis on practical clinical applications, all the chapters in the second part of the book have been written by clinical specialists practicing in the individual areas of disease. The book is so designed that clinicians may be able to read the relevant chapters in the second part of the book in isolation, using the basic science aspects contained in the first part of the book as reference chapters.

This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.

This volume is the first of its kind to emphasize the visual approach in the diagnosis of cutaneous lymphoid infiltrates. Written and designed in an accessible yet highly detailed format by an expert in the field, this book bridges the knowledge gaps so often found when dealing with skin lymphomas. Complete with more than two hundred high quality images and illustrations, Diagnosis of Cutaneous Lymphoid Infiltrates offers pearls and pitfalls as well as differential diagnoses. Additionally, images are explained and decoded with the use of illustrations and analogies, proving to be an invaluable resource for pathologists, dermatologists, dermatopathologists, hematopathologists, and residents and fellows in these fields.

Authoritative experts in transfusion medicine describe in critical detail the most important procedures for obtaining, selecting, and transfusing red blood cells to patients. The topics covered include such key issues as transfusion problems in the immunocompromised, the complications of autoantibodies, transfusion of infants with hemolytic disease, difficulties arising from solid organ transplantation, stem cell transfusions, and the challenges of massive transfusion. Also discussed are the use, limitations, and alternatives to autogeneic cells; long-term red cell transfusion; the management of adverse reactions to red cell transfusions; and the question of blood group antigens and their association with disease and differential diagnosis. The book offers transfusion specialists fresh insights and information to maximize and extend their current knowledge.

Hematopathology: Genomic Mechanisms of Neoplastic Diseases will keep physicians abreast of the rapid and complex changes in genomic medicine, as exemplified by the molecular pathology of hematologic malignancies. This timely volume will update physicians on the complexities of genomic lesions, as well as offer an integrated framework encompassing molecular diagnosis, the new WHO classification of hematologic neoplasms with focus on molecular pathology, prognostic value of molecular tests, and molecular monitoring of response to gene-targeted therapy. As such, it will be of great value to hematologists, oncologists, pathologists, internal medicine and pediatric specialists, as well as bioscientific staff and laboratorians in private hospitals and academic institutions.

Multiple myeloma is the second most common hematologic malignancy and c- rently affects approximately 50,000 people in the United States. Each year about 20,000 people are diagnosed with myeloma. Although new treatments have been developed, which signi?cantly prolong the survival of patients, myeloma bone d- ease still remains a major cause of severe morbidity and increased mortality in patients with myeloma. Myeloma bone disease is characterized by "punched out" lytic lesions caused by increased osteoclastic bone destruction accompanied by suppressed or even absent osteoblast activity. Advances in our understanding of both the pathophysiology of myeloma bone disease and the development of novel agents that target speci?c pathways involved in both the increased osteoclast f- mation and the suppressed osteoblast activity in myeloma provide new hope for these patients. The treatment of myeloma bone disease was revolutionized by cl- ical trials that demonstrated the signi?cant bene?t of intravenous bisphosphonate therapy in patients with myeloma bone disease. With the identi?cation of many of the cytokines and chemokines involved in myeloma bone disease, novel th- apies such as denosumab that blocks RANKL activity, anti-DKK1, which targets the inhibition of osteoblast activity by blocking Wnt signaling inhibition, and the potential anabolic effects of agents such as bortezomib and activin have greatly improved our potential to block the progression or reverse myeloma bone disease.

Exciting new "biologic" therapies for treating leukemia are appearing so rapidly that clinicians often find it difficult to make informed decisions about their use when making patient treatment decisions. Biologic Therapy of Leukemia summarizes and reviews all the available data concerning these cutting-edge biologic therapies so that practicing clinicians can make the correct patient-care choices. Here the busy physician will find in one convenient place crucial information on the uses and limitations of the major biologic therapies for leukemia, the different biologic strategies for its treatment, the management of patients being treated with such biologic agents, and the current and future role of emerging biologic agents.

Inspite of considerable progress in prevention, diagnosis, and treatment, pulmonary embolism has remained a threat to the patient and a challenge for the physician both in conservative, as well as in operative disciplines. Pulmonary embolism is according to pathology observations still the most frequently overlooked clinical diagnosis. In 1-5 per 100 autopsies, clinically unexpected pulmonary emboli are found. In addition, the sequelae of recurrent pulmonary emboli, the syndrome of pulmonary hypertension with or without right heart failure, continues to present a therapeutic dilemma - and no progress is in sight. In intensive care medicine pulmonary embolism, either acute, massive, and/or recur- rent, continues to be both a therapeutic as well as a preventive challenge mobilizing pharmacotherapeutic, catheter-interventional, and operative resources. Diagnostic, therapeutic, and preventive strategies are currently in use. Their basis, however, seems surprisingly thin, as far as our knowledge on the natural course of this chameleon-like illness with and without fibrinolytic, anticoagulative, catheter or opera- tive treatment is concerned. A large European multicenter register has been initiated by Professors Kasper and Geibel with the help of Boehringer Ingelheim Pharmaceutics, in order to better describe the natural course of pulmonary embolism under current treat- ment modalities. Furthermore, recently the clinical significance of the valve patent foramen ovale as a source of paradoxical emboli is beginning to be better understood. Many concepts therefore require revision.

A short, up-to-date text on blood groups, for people working or training in the field of blood transfusion, transplantation, or human genetics, but who are not specialising in the field of blood groups, the third edition of Essential Guide to Blood Groups is a pocket-sized book, containing full colour text together with schematic figures and tables. The book comprises an introduction to blood groups, followed by chapters on techniques, information on various blood groups, antibodies, quality assurance in immunohaematology, and it concludes with chapters on troubleshooting in the laboratory, and FAQs. It also covers the serology, inheritance, biochemistry and molecular genetics of the most important blood group systems.

The rates of acute leukemia cure have gradually improved over the last decade. Clinical study results reflect the impact of chemotherapy intensity and duration, the role of prolonged maintenance, intensified consolidation or very early intensification. Further progress has also been achieved in bone marrow trans plantation, and recent prospective studies and meta-analyses have contributed comparisons of the high antileukemic efficacy of bone marrow transplantation to that of improved chemotherapy. This allows a more successful combining of the two forms of treatment. New prognostic factors have emerged from both cytogenetic and molecular genetic research. Thus, the Philadelphia chromosome translocation and the bcr/abl gene rearrangement have proven to be the dominating risk factor in acute lymphoblastic leukemia. Since the frequency increases with age, differences in prognosis between children and adults can be explained. Evaluation of molecular and immunologic leukemia cell markers has provided a better understanding of residual leukemia in clinical remission, as a prognostic factor and in monitoring the effectiveness of the antileukemic strategy. Recent work on leukemic cell biology has resulted in novel therapeutic approaches such as terminal differentiation by all-trans-retinoic acid, modulation of chemotherapy by hematopoietic growth factors such as GM-CSF and enhancement of immunologic control by cytokines such as interleukin 2. New antimicrobial drugs and the application of mostly empiric anti-infectious strategies have helped reducing the therapeutic risk. Thus, a number of recent achievements have provided us with new options in the management of patients with acute leukemias."

J. DE GROOTE One of the most ominous and troublesome complications of the liver disease is the appearance of hemorrhagic phenomena. Many careful clini- cal observations about the relationship of liver function and of bilia- ry tree pathology have been published. A vast amount of research work has been devoted to the subject. The severity of the hemorrhagic disor- der is usually in relation to the liver disease. In mild chronic hepa- titis or short lasting obstruction slight subcutaneous or mucosal blee- ding may (lraw the attention of the patient and the doctor, but they are as such far from dangerous. However in acute hepatic insufficiency, in biliary cirrhosis the bleeding tendency is to be considered as a life threatening complication in about half of the cases. Moreover coagulation disturbances aggravate bleeding not only from ruptured oesophageal or gastric varices but also from gastritis or peptic ulcer. 11enometrorrhagia, epistaxis and gingival bleeding may be very trouble- some in these conditions. The use of diagnostic procedures sucl. as liver puncture biopsy and peritoneoscopy are often impossible when platelets and prothrombine time are too low. In order to overcome this difficul- ty a procedure has been worked out taking a biopsy through a trans- jugular catheter placed in the hepatic vein. If a bleeding from the liver occurs it will be in the circulatory system and not cause any trouble.

A medical book need not be pretty, but it must be necessary and informative. This monograph on the clinical and diagnostic pathology of graft-versus-host disease, provid ing detailed visual information on the histo morphological and immunohistological fea tures of GvHD, is intended to close a gap in the otherwise comprehensive medical literature on GvHD. B. Heymer Acknowledgements No one accumulates knowledge alone. lowe thanks to: Prof. G. R. F. Kruger, Houston, for introducing me to the histomorphological analysis of GvHD Prof. R. Arnold, Berlin, for many fruitful clinico pathological discussions Prof. K. H. Muller-Hermelink, Wurzburg, for expert advice in difficult histological differential diagnoses Prof. W. Mohr, Ulm, for continuous support and encouragement in moments of fatigue Last, but by no means least, Mrs. R. Endres-Klein, Ulm, without whom the preparation of this book would have been impossible In addition, I am grateful to the editorial staff at Springer, Heidelberg. B. Heymer Contents 1 Introduction. . . . . . . . . . . . . 1 1. 1 What Is Graft-Versus-Host Disease? 1 1. 2 Has the Pathology of GvHD Changed in the Past Decades? . . . . 1 1. 3 Why Write a Synopsis of the Clinical and Diagnostic Pathology of GvHO? 2 2 Occurrence of GvHD . . . . . . . . . 5 2. 1 GvHD After Allogeneic Bone Marrow Transplantation . . . . . . . . . . . . . 6 2. 2 GvHD After Allogeneic Peripheral Blood Stem Cell Transplantation 6 2. 3 Alternative Donors . . . . . . . . . . . . 7 2. 4 Umbilical Cord Blood . . . . . . . . . . 7 2. 5 GvHD After Materno-fetal Transfusion 8 2. 6 GvHD After Blood Transfusion . . . . . 9 2."

International experts not only review the state-of-the-art in managing children and adults with acute leukemia, but also debate the pros and cons of current controversial and problematic issues. The book summarizes the best diagnostic and treatment practices for acute leukemias in children, adolescents, and adults. Among the therapies discussed are methotrexate, asparaginase, antipurines, epipodophyllotoxins, hematopoietic stem cell transplantation, hematopoietic growth factors, and immunotherapy.

Hemoglobin and Hemoglobinologists This volume, Hemoglobin Disorders: Molecular Methods and Protocols, will be introduced with a review of the great milestones in the field, and the scientists responsible for those achievements. The history of hemoglobin can be divided into three periods: the Classical period, the Modern period, and the Post-Modern period. I am inclined to include as the four major members of the classical period Francis Roughton, Quentin Gibson, Jeffries Wyman, and Linus Pauling, not only because of their achievements, but also because of the superb scientists they trained and/or influenced. Francis John Worsely Roughton (1899-1972) (Fig. 1), in his laboratory at Trinity College in Cambridge, England, made the first measurements of the rapid reaction of oxygen with hemoglobin at the millisecond scale, at first by flow-mixing methods and later by flash photolysis. He not only opened an era of molecular research of hemoglobin, but also invented the methodology for fast reactions through the use of laser technology, which was later improved by others so that even faster reactions could be detected. Another contribution of Roughton was the education of Quentin H. Gibson (Fig. 2), his favorite s- dent, who, in his laboratory in Sheffield, continued to expand the horizon of ligand binding to hemoglobin, defining the oxygen binding constants for each of the hemes of hemoglobin. Though this did not, as expected, solve the und- lying mechanism of ligand cooperativity as discussed below, it was nonet- less an important milestone.

Now in its second edition, Modern Hematology: Biology and Clinical Management reflects the major advances in the understanding, diagnosis, and treatment of blood disorders. It describes the latest clinical and scientific developments as well as details targeted and molecular therapies. The book brings together facts, concepts, and protocols important for the practice of hematology. In 23 chapters, all major blood diseases are covered, as well as rare diseases that are of scientific interest. As in the previous edition, each chapter is illustrated by tables, figures, and a selection of color plates.

In Leukemia and Lymphoma: Detection of Minimal Residual Disease, hands-on experts describe and discuss the minimal residual disease (MRD) methods they have successfully pioneered for leukemias and lymphomas. They apply reverse transcription PCR (RT-PCR) to acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and acute promyelocytic leukemia (APL). Other PCR methods are used for Non-Hodgkin's Lymphoma and for the monitoring of follicular lymphoma. Additional chapters address the use of real-time quantitative PCR (RQ-PCR), the emergent method of choice, in patients with acute lymphoblastic leukemia (ALL), the evaluation of MRD techniques in clinical trials, and the application of flow cytometry techniques.

A comprehensive and critical review of the latest scientific advances in our understanding of the molecular genetics and biology of CLL and their application to the best management of CLL. The authors focus on diagnosis, prognosis, multifaceted treatment options, and complications. Among the diverse treatments considered are chemotherapy, autologous and allogenic transplantations, monoclonal antibody therapy, immunotoxin therapy, gene therapy, and several new therapeutic strategies. Familial and juvenile chronic lymphocytic leukemia are also discussed.

In general, several mathematical models can be designed in order to describe a biological or medical process and there is no unique criterion which model gives the best description. This book presents several of these models and shows applications of them to different biological and medical problems. The book shows that operations research expertise is necessary in respect to modeling, analysis and optimization of biosystems.

This is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas.

The extravasation of cytotoxic agents can result in severe local tissue damage and medical emergencies during tumour therapy. This revised compendium is intended to help clinicians assess any situation speedily and with certainty. The general section of the book includes topics such as predisposition, prevention, type of harm, general measures in handling extravasated drugs, specific antidotes, and documentation. In the 2nd edition, the scientific information contained in the general section and relating to the actual substances has been updated. The substance specific part of the book includes detailed instructions on handling more than 50 cytotoxic drugs, to initiate targeted measures. Templates for an extravasation set, overview tables, documentation sheets, and patient information, as we as a CD-ROM are included to support clinical practice. The book is the outcome of a consensus of an interdisciplinary working group that has collected and systematically reviewed all published literature on the topic.